Disease and treatment patterns for advanced cholangiocarcinoma: A multicentric study from Portugal

Meeting Gastrointestinal Cancers Congress of the European-Society-for-Medical-Oncology (ESMO) Background: Gemcitabine plus cisplatin (GC) was standard first-line treatment for advanced biliary tract cancers until recently, supported by the UK ABC-02 study. However, TOPAZ-1 showed survival improvement with Durvalumab plus GC. Nevertheless, a significant proportion of patients face challenges with GC tolerability, prompting into alternatives such as gemcitabine and carboplatin (GCb). Moreover, there remains a paucity of stratified data pertaining to cholangiocarcinomas (CCA). We analyzed 5-year trends to determine treatment rates and cisplatin use in the real world.

URI

http://hdl.handle.net/10400.1/26205

Editora

Elsevier

DOI

10.1016/j.annonc.2024.05.456

Coleções

ULS_10.1-MED-Artigos

Licença CC

Sem licença CC

Métricas Alternativas

Ver registo completo